Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
This study has been terminated.
Study NCT00057343   Information provided by Biogen Idec

First Received on March 31, 2003.   Last Updated on September 8, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Non-Hodgkin's Lymphoma
Additional conditions recognized in this trial
Lymphoma
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Zevalin (ibritumomab tiuxetan)
Rituxan (rituximab)
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Rituximab
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Biogen Idec


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services